Company intelligence / Profile preview

Tianjin Chase Sun Pharmaceutical

Tianjin, Tianjin, Chinahxchem.net ↗

Ownership: Private
Development stage: Other

Overview

Tianjin Chase Sun Pharmaceutical is a diversified pharmaceutical company with commercialized products in China and internationally. Its portfolio includes modern traditional Chinese medicines such as Xuebijing Injection (approved for sepsis and COVID‑19), small molecules for various indications including oncology and respiratory disease, as well as ongoing clinical programs targeting PD-L1 (brain cancer) and other mechanisms. The company has GMP-certified manufacturing capabilities for APIs and finished dosage forms.

Therapeutic areas: NeurologyPulmonologyInfectious DiseasesOncologyImmunologyCardiovascular
Modalities: Small moleculeHerbal medicinePeptides
Industry: Biotech

Drug pipeline

4 assets

xuebijing

3 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Tianjin Chase Sun Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tianjin Chase Sun Pharmaceutical.

Explore the full profile